Clearmind Medicine Inc.CMNDNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank88
3Y CAGR-56.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-56.2%/yr
Annual compound
Percentile
P88
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 50.14% |
| 2024 | -9.41% |
| 2023 | -52.26% |
| 2022 | 594.87% |
| 2021 | 0.00% |
| 2020 | 0.00% |
| 2019 | 0.00% |
| 2018 | 0.00% |
| 2017 | 0.00% |